Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1957 1
1958 4
1959 2
1960 3
1961 1
1962 3
1963 3
1964 11
1965 11
1966 14
1967 14
1968 26
1969 28
1970 43
1971 36
1972 54
1973 94
1974 94
1975 217
1976 187
1977 191
1978 192
1979 181
1980 253
1981 232
1982 285
1983 303
1984 327
1985 320
1986 315
1987 351
1988 361
1989 371
1990 459
1991 482
1992 535
1993 549
1994 572
1995 588
1996 605
1997 646
1998 694
1999 657
2000 740
2001 724
2002 839
2003 851
2004 866
2005 981
2006 1076
2007 1120
2008 1086
2009 1147
2010 1222
2011 1247
2012 1312
2013 1279
2014 1396
2015 1401
2016 1311
2017 1303
2018 1405
2019 1359
2020 1416
2021 1438
2022 1133
2023 1004
2024 358

Text availability

Article attribute

Article type

Publication date

Search Results

34,860 results

Results by year

Filters applied: . Clear all
Page 1
Glucocorticoids.
Adcock IM, Mumby S. Adcock IM, et al. Handb Exp Pharmacol. 2017;237:171-196. doi: 10.1007/164_2016_98. Handb Exp Pharmacol. 2017. PMID: 27864677 Free article. Review.
Targeting the defective pathways associated with GC function in these patients may also reactivate GC responsiveness....
Targeting the defective pathways associated with GC function in these patients may also reactivate GC responsiveness....
Response to Glucocorticoid Therapy in Patients with Mild to Moderate Coronavirus Disease 2019 at a Japanese Care Facility.
Kikuchi A, Arita R, Ono R, Tadano Y, Saito N, Akaishi T, Kanno T, Osawa M, Takayama S, Abe M, Onodera K, Ishii T. Kikuchi A, et al. Tohoku J Exp Med. 2022 Jun 4;257(2):97-106. doi: 10.1620/tjem.2022.J022. Epub 2022 Apr 7. Tohoku J Exp Med. 2022. PMID: 35387909 Free article.
The median number of days from glucocorticoid administration to hospitalization was 1.0 day (range, 1.0-1.0 day). In the non-hospitalized patients, the median number of days of glucocorticoid administration was 5.0 days (5.0-5.25 days). The mean number of days from …
The median number of days from glucocorticoid administration to hospitalization was 1.0 day (range, 1.0-1.0 day). In the non-hospital …
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Czock D, Keller F, Rasche FM, Häussler U. Czock D, et al. Clin Pharmacokinet. 2005;44(1):61-98. doi: 10.2165/00003088-200544010-00003. Clin Pharmacokinet. 2005. PMID: 15634032 Review.
Thus, inflammation and immune response mechanisms may be modified. Nongenomic mechanisms might play an additional role in glucocorticoid pulse therapy. ...These simulations suggest that the clinical efficacy of low-dose glucocorticoid regimens might be …
Thus, inflammation and immune response mechanisms may be modified. Nongenomic mechanisms might play an additional role in glucocor …
Rheumatoid arthritis: advances in treatment strategies.
Prasad P, Verma S, Surbhi, Ganguly NK, Chaturvedi V, Mittal SA. Prasad P, et al. Mol Cell Biochem. 2023 Jan;478(1):69-88. doi: 10.1007/s11010-022-04492-3. Epub 2022 Jun 21. Mol Cell Biochem. 2023. PMID: 35725992 Review.
Rheumatoid arthritis (RA) is characterised by severe joint and bone damage due to heightened autoimmune response at the articular sites. Worldwide annual incidence and prevalence rate of RA is 3 cases per 10,000 population and 1%, respectively. ...However, certain adverse …
Rheumatoid arthritis (RA) is characterised by severe joint and bone damage due to heightened autoimmune response at the articular sit …
Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract.
Biavasco F, Ihorst G, Wäsch R, Wehr C, Bertz H, Finke J, Zeiser R. Biavasco F, et al. Bone Marrow Transplant. 2022 Oct;57(10):1500-1506. doi: 10.1038/s41409-022-01741-3. Epub 2022 Jun 29. Bone Marrow Transplant. 2022. PMID: 35768570 Free PMC article.
A total of 144 patients developed GI-GVHD and 82 (57%) were resistant to glucocorticoid-therapy (SR). The most commonly used second-line therapy was ruxolitinib (74%). ...These findings indicate that therapy response of SR-GI-GVHD to different i …
A total of 144 patients developed GI-GVHD and 82 (57%) were resistant to glucocorticoid-therapy (SR). The most commonly used s …
Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Pofi R, Caratti G, Ray DW, Tomlinson JW. Pofi R, et al. Endocr Rev. 2023 Nov 9;44(6):975-1011. doi: 10.1210/endrev/bnad016. Endocr Rev. 2023. PMID: 37253115 Free PMC article. Review.
It is estimated that 2% to 3% of the population are currently prescribed systemic or topical glucocorticoid treatment. The potent anti-inflammatory action of glucocorticoids to deliver therapeutic benefit is not in doubt. ...The coprescription of existing licensed d …
It is estimated that 2% to 3% of the population are currently prescribed systemic or topical glucocorticoid treatment. The potent ant …
Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials.
Bruce IN, van Vollenhoven RF, Psachoulia K, Lindholm C, Maho E, Tummala R. Bruce IN, et al. Lupus Sci Med. 2023 Jan;10(1):e000761. doi: 10.1136/lupus-2022-000761. Lupus Sci Med. 2023. PMID: 36639192 Free PMC article.
Anifrolumab 300 mg and placebo groups were compared for British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response over time, time to sustained BICLA response, SLE Responder Index 4 (SRI(4)) response over time, time to sustained Cu …
Anifrolumab 300 mg and placebo groups were compared for British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) res …
The Biologist's Guide to the Glucocorticoid Receptor's Structure.
Deploey N, Van Moortel L, Rogatsky I, Peelman F, De Bosscher K. Deploey N, et al. Cells. 2023 Jun 15;12(12):1636. doi: 10.3390/cells12121636. Cells. 2023. PMID: 37371105 Free PMC article. Review.
The glucocorticoid receptor alpha (GRalpha) is a member of the nuclear receptor superfamily and functions as a glucocorticoid (GC)-responsive transcription factor. GR can halt inflammation and kill off cancer cells, thus explaining the widespread use of gl …
The glucocorticoid receptor alpha (GRalpha) is a member of the nuclear receptor superfamily and functions as a glucocorticoid …
Optimal glucocorticoid therapy.
Debono M, Ross RJ. Debono M, et al. Endocr Dev. 2011;20:173-180. doi: 10.1159/000321241. Epub 2010 Dec 16. Endocr Dev. 2011. PMID: 21164270 Review.
Loss of the endogenous cortisol rhythm is associated with sleep disturbance, depression, and metabolic abnormalities. In adrenal insufficiency, current glucocorticoid replacement regimens cannot replace the normal circadian rhythm of cortisol, and patients have an increase …
Loss of the endogenous cortisol rhythm is associated with sleep disturbance, depression, and metabolic abnormalities. In adrenal insufficien …
New concepts to reduce glucocorticoid toxicity.
Alten R, Mischkewitz M. Alten R, et al. Joint Bone Spine. 2019 Nov;86(6):715-723. doi: 10.1016/j.jbspin.2018.11.006. Epub 2018 Dec 5. Joint Bone Spine. 2019. PMID: 30528678 Review.
The Glucocorticoid Toxicity Index is a method to measure side effects of glucocorticoid therapy objectively and will be central in future studies comparing different therapy regimes. ...Still, confirmation of these first data in further trials will be …
The Glucocorticoid Toxicity Index is a method to measure side effects of glucocorticoid therapy objectively and will be …
34,860 results
You have reached the last available page of results. Please see the User Guide for more information.